Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Funding knowledgebases: Towards a sustainable funding model for the UniProt use case.

Gabella C, Durinx C, Appel R.

Version 2. F1000Res. 2017 Nov 27 [revised 2018 Jan 1];6. pii: ELIXIR-2051. doi: 10.12688/f1000research.12989.2. eCollection 2017.

2.

Bioinformatics on a national scale: an example from Switzerland.

Baillie Gerritsen V, Palagi PM, Durinx C.

Brief Bioinform. 2017 Jul 4. doi: 10.1093/bib/bbx073. [Epub ahead of print]

PMID:
29106442
3.

Identifying ELIXIR Core Data Resources.

Durinx C, McEntyre J, Appel R, Apweiler R, Barlow M, Blomberg N, Cook C, Gasteiger E, Kim JH, Lopez R, Redaschi N, Stockinger H, Teixeira D, Valencia A.

Version 2. F1000Res. 2016 Sep 30 [revised 2017 Jan 1];5. pii: ELIXIR-2422. doi: 10.12688/f1000research.9656.2. eCollection 2016.

4.

[Bio-informatic and personalized medicine: Switzerland is pioneer].

Gerritsen VB, Barbié V, Durinx C, Beckmann JS.

Rev Med Suisse. 2016 Feb 24;12(507):414-6. French. No abstract available.

PMID:
27039608
5.

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

Lambeir AM, Durinx C, Scharpé S, De Meester I.

Crit Rev Clin Lab Sci. 2003 Jun;40(3):209-94. Review.

PMID:
12892317
6.

Presence and release of SR-17 (chromogranin B(586-602)) in the porcine splenic nerve and its enzymatic degradation by CD26/dipeptidyl peptidase IV.

Depreitere J, Durinx C, Wang Z, Coen E, Lambeir AM, Scharpé S, De Potter W, Nouwen EJ.

Regul Pept. 2002 Jun 15;106(1-3):71-9.

PMID:
12047913
7.

Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.

Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir AM, Neyts J, Liekens S, Maudgal PC, Billiau A, Van Damme J.

Blood. 2001 Dec 15;98(13):3554-61.

8.

Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.

Lambeir AM, Durinx C, Proost P, Van Damme J, Scharpé S, De Meester I.

FEBS Lett. 2001 Nov 2;507(3):327-30. Erratum in: FEBS Lett 2002 Feb 13;512(1-3):353.

9.

Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family.

Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, Scharpé S, Van Damme J, De Meester I.

J Biol Chem. 2001 Aug 10;276(32):29839-45. Epub 2001 Jun 4.

10.

Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters.

Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I.

Clin Chem Lab Med. 2001 Feb;39(2):155-9.

PMID:
11341750
11.

Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides.

Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, Scharpé S, De Meester I.

Eur J Biochem. 2000 Sep;267(17):5608-13.

12.

Lowered serum dipeptidyl peptidase IV activity in patients with anorexia and bulimia nervosa.

van West D, Monteleone P, Di Lieto A, De Meester I, Durinx C, Scharpe S, Lin A, Maj M, Maes M.

Eur Arch Psychiatry Clin Neurosci. 2000;250(2):86-92.

PMID:
10853924
13.

Natural substrates of dipeptidyl peptidase IV.

De Meester I, Durinx C, Bal G, Proost P, Struyf S, Goossens F, Augustyns K, Scharpé S.

Adv Exp Med Biol. 2000;477:67-87. Review. No abstract available.

PMID:
10849732
14.

The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.

Augustyns K, Bal G, Thonus G, Belyaev A, Zhang XM, Bollaert W, Lambeir AM, Durinx C, Goossens F, Haemers A.

Curr Med Chem. 1999 Apr;6(4):311-27. Review.

PMID:
10101215
15.

Specific inhibition of CD26/DPP IV enzymatic activity in allograft recipients: effects on humoral immunity.

Korom S, De Meester I, Schmidbauer G, Pratschke J, Brendel MD, Durinx C, Schwemmle K, Haemers A, Scharpé S, Kupiec-Weglinski JW.

Transplant Proc. 1999 Feb-Mar;31(1-2):778. No abstract available.

PMID:
10083329
16.

Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha.

Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP, De Clercq E, De Meester I, Van Damme J.

FEBS Lett. 1998 Jul 31;432(1-2):73-6.

Supplemental Content

Loading ...
Support Center